Data from Inovalon's MORE(2) Registry® Enables Medication Adherence And Persistence Research Research to be Presented at the Society for Medical Decision Making 35th Annual Meeting
BOWIE, Md., Oct. 15, 2013 /PRNewswire/ -- Inovalon, Inc., a leading provider of data-driven healthcare solutions, today announced a medication adherence research study to be presented at the Society for Medical Decision Making (SMDM) 35th Annual Meeting October 19–23 in Baltimore, MD. The study was supported by data from Inovalon's Medical Outcomes Research for Effectiveness and Economics Registry (MORE2 Registry®).
Inovalon researchers will present "Comparative Medication Adherence Rates across the Different Classes of Renin-Angiotensin-Aldosterone System (RAS) Antihypertensive Drugs in Patients with Hypertension." This study addresses a high priority research need recognized in a 2011 Agency for Healthcare Research and Quality (AHRQ) comparative effectiveness review, which identified a gap in observational research examining differences in longitudinal adherence rates across the different RAS antihypertensive drug classes. The analysis is known to be the first to provide a drug class-level comparison of adherence to all three RAS antihypertensive drug classes using a large nationally representative administrative database. This study found differential adherence to long-term RAS antihypertensive therapy that provides new information regarding the effectiveness of specific antihypertensive medications in preventing cardiovascular events that could impact optimal prescribing practices and overall outcomes and healthcare costs. Adherence to RAS drugs is also an important health plan quality measure, and this research can help guide optimal treatment protocols and improve health plan quality ratings. The presentation will be held during Session I on Sunday, October 20th, starting at 6:30 pm.
"Inovalon is using sophisticated statistical analysis tools and the power of large longitudinal data to better understand outcomes related to various treatment protocols and health services," said Christie Teigland, PhD, Director of Statistical Research at Inovalon. "This research will support development of evidence based guidelines and practices better tailored to individual patient characteristics and help clinicians both predict and prevent related adverse outcomes."
Inovalon's Statistical Research Team co-authors include: Sandhya Mehta, PhD; Reshma Bhattacharjee, MBBS, MPH, MS; Ping Chen, MD; Barton T. Jones, MS; Alexis Parente, MA; Zulkarnain Pulungan, PhD; John F. Scoggins, PhD; Xiaoqin Yang, PhD; Bin Zhang, MS; and Christie Teigland, PhD.
About Inovalon, Inc.
Inovalon, Inc. is a leading technology-enabled healthcare solutions provider focused on the importance of healthcare data and its ability to drive dramatic, objective improvement in clinical and quality outcomes, care management and financial performance throughout the healthcare community. Proprietary healthcare datasets, aggregation and analysis capabilities, combined with a national infrastructure of leading-edge technology, clinical prowess and deep human resources, empower Inovalon's advanced generation of healthcare assessment and improvement through highly informed solutions. Driven by data, Inovalon uniquely identifies gaps in care, quality, data integrity, and financial performance – while also bringing to bear the resources to resolve them. This differentiating combination provides a powerful capability suite, touching more than 540,000 physicians, 220,000 clinical facilities, and more than 120 million Americans, driving high‐value impact, improving the quality and economics for health plans, hospitals, physicians, patients, and researchers. Please visit www.inovalon.com for more information.
SOURCE Inovalon, Inc.